Risks in Discontinuation Trials With Antidepressants

To the Editor: US Food and Drug Administration investigators recently reported on “maintenance trials for major depressive disorder” submitted for regulatory review, based, remarkably, on anonymous sources and unspecified treatments.1 Trials involved initial, randomized treatment for acute depression followed by re-randomization to continue successful treatment or discontinue to placebo up to another 8.88 (95% CI, 6.68–10.3) months. All 15 trials found significantly later relapses with antidepressants than with placebo.1 Because such consistent superiority of antidepressants over placebo is very unusual,2,3 trial design may have had an important influence. Only subjects responding, in the short term, to a test drug could enter a discontinuation phase, with inevitable selection bias. As brief periods of “clinical stabilization” were allowed before discontinuation of treatment, participants probably varied in degree of partial recovery. It is not reported whether there were systematic attempts to remove treatment gradually so as to limit risk of discontinuation-associated relapses, which can arise over many weeks after discontinuing antidepressants and are sensitive to drug discontinuation rate.4

A total of 1,743 recovering subjects were re-randomized to placebo, and 2,131 were randomized to continue antidepressant treatment. Data reported support random-effects meta-analysis of relapse rates (36.2% [95% CI, 30.2%–42.1%] with discontinued vs 18.4% [13.2%–23.7%] with continued antidepressants), which indicates a highly significant pooled placebo-over-drug relapse rate-ratio (RR = 1.84 [1.66–2.03]; z = 8.38, P < .0001). In only 1 trial (L) was the drug-placebo difference nonsignificant (RR = 1.41, 0.95–2.08), contrasting to uniform success based on survival analysis of time to relapse—an outcome measure that remains insufficiently evaluated for application to therapeutic trials.5

Most placebo-relapses occurred within 1–3 months, when drug-placebo differences were substantial, but the differences were much smaller thereafter (see Figures 1–3 in article).1 This pattern may simply indicate that more vulnerable persons relapsed earlier, or it may reflect treatment discontinuation stress.4 More prolonged clinical stability may reduce such effects: trial N provided little placebo differences were substantial, but the differences were much smaller thereafter (see Figures 1–3 in article).1 This pattern may simply indicate that more vulnerable persons relapsed earlier, or it may reflect treatment discontinuation stress.4 More prolonged clinical stability may reduce such effects: trial N provided little


dr. Borges was shown this letter and declined to comment.

References

Ross J. Baldessarini, MD
rbaldessarini@mclean.harvard.edu

Author affiliation: Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

Potential conflicts of interest: None reported.

Funding/support: Supported, in part, by a grant from the Bruce J. Anderson Foundation and by the McLean Private Donors Research Fund.


© Copyright 2014 Physicians Postgraduate Press, Inc.